September 17th 2024
Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.
September 16th 2024
Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
November 7th 2022“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Patient Risk Stratification and Evolving Imaging Modalities in Prostate Cancer
November 7th 2022Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.
Yale professors create new drug that could combat prostate cancer
October 12th 2022A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancer
September 28th 2022Adding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Dr. Linehan on her experience and learning curve with HIFU
September 28th 2022“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.
Consider financial toxicity when recommending novel hormonal therapies for prostate cancer
September 27th 2022"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.
Pushing past the pandemic’s impact on prostate cancer screening
September 26th 2022"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.
Investigators evaluate out-of-pocket costs for advanced prostate cancer treatments
September 23rd 2022“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.
Cholesterol-lowering drug tested for effect on prostate cancer tumors
August 31st 2022“We have a much larger minority population, and so the ability for us to identify how this type of intervention may impact a variety of minority or underserved populations is interesting,” said Stephen Savage, MD, vice chairman of the Department of Urology.
Clinic helps patients prepare to move beyond prostate cancer
August 16th 2022“The benefit of the clinic is a holistic approach to the survivorship care that takes into account things that we as urologists don’t usually consider in our everyday patient encounters,” said Niels Johnsen, MD, MPH, assistant professor of Urology, Division of Reconstructive Urology and Pelvic Health, Vanderbilt University Medical Center.